Investing in the pharmaceutical world means trying to invest as a product gets closer to completing FDA trials and approvals. In many respects, this is a wise strategy as a negative review by the FDA can kill a drug and its sponsor right along with it. From another point of view, taking the longer term view and dictating return terms can be a better way of investing if the product and company seem to be moving in the right direction. Generally, this could be thought of as the next quarter syndrome versus the next year(s) reward concept. The first concept got the economy where it is today. The second can hold hope for a larger more controlled return.
CardioVascular Biotherapeutics Inc., a biopharmaceutical company, works to develop medications for sever cardiac and wound care conditions. The company is currently beginning Phase II trials for its lead product and continues development in clinical trials for three additional products directed at wound care.
By all accounts, the company is making significant progress with its trials and testing. It is currently starting Phase II – severe coronary heart disease – trials for its Fibrobalst 1 (FGF-1 141) product. Although the protein based product is envisioned for increasing blood flow in heart blood vessels, it is thought that other organs will be able to take advantage of its effects as well. The company has been finding excellent successes for several of its wound care drugs as well. The topical protein based treatments have been privately funded to a minimum of $3 million and could reach a maximum of $18 million as warranted.
As one might suspect, the company is focusing on the Phase II trials of its coronary protein product, as it is closer to market. The company’s three other products, however, may offer a wider spectrum of user and the potential for longer term returns. Diabetic wound care and various other stasis leg wound issues are a very large market as it is, and have expectation of accelerated growth in the long term. The cardiac product will likely provide solid revenues, but it may work out that over the longer term per patient revenue will tilt toward the wound care product.
Derma Life, the current leading funder of the wound care product clinical trials, appears to be viewing the longer term in its investment choices and may benefit. If other investors do the same, they may also be on a straight line to profit when the products make it to market.
Let us hear your thoughts below:
CardioVascular BioTherapeutics, Inc. (CVBT.OB) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease. Cardiovascular disease is the worldwide leading cause of death.
The Company is developing injectable and topical formulations of their already active pharmacological ingredient (API) in order to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia). The Company’s API contains FGF-1141; a human protein manufactured using a proprietary technology. FGF-1 stimulates the growth and proliferation of the three main cell types of blood vessels; endothelial cells, smooth muscles cells and pericytes.
The Company’s lead drug candidate successfully completed initial clinical trials in Germany during the 1990s, with no drug-related adverse events and a statistically significant increase in localized blood vessel growth (and perfusion). Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered via injection in severe CHD patients.
CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of FGF-1141 aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral artery disease, and pledges to continue exploration for additional applications of FGF-1.
Let us hear your thoughts: CardioVascular BioTherapeutics, Inc. Message Board
CardioVascular BioTherapeutics’ lead heart disease medication has been granted Phase II testing permission after solid results were found in Phase I trials. Phase II catheter and placebo tests promise to move this quality of life medication one step closer to final approvals.
The bioscience company is involved in developing drug treatments designed to help people with critical heart disease issues. It is also involved in developing a drug treatment that helps with the healing process of wounds and lesions associated with diabetes. As with any bioscience company, getting the drug treatments through the testing and approvals process is the main struggle, past developing the drug.
CardioVascular BioTherapeutics is well along the critical path of testing and approvals having completed the Phase I portion of approvals and receiving permission for Phase II catheter and placebo tests, with regards to its heart disease drug. Phase I testing showed a marked improvement in critical care heart disease patients that had little or no recourse except to try an experimental medication.
Although there may be similarities to other heart disease medications, the company’s medication works to help grow new blood vessel systems around the affected areas. As the new blood vessel systems are formed increased blood flow results. Increased blood flow leads to increased oxygen and nutrient capacity and better opportunity for quality of life where once there was little hope.
CardioVascular BioTherapeutics’ diabetes wound care medication is currently in its Phase I testing process and showing positive indicators. The sheer number of diabetic patients that could make use of this possible wound care medication makes taking a strong look at the company compelling.
The company currently has a series of other drug trials in the pipeline at various stages of development and approvals. Given the nature of the approvals process the future of these drugs is unknown. If, however, current drug testing of current products is an indication, a solid potential exists for this company.
Let us hear your thoughts below:
Shares of CardioVascular BioTherapeutics Inc. (OTCBB: CVBT) rose 16.3 percent Friday to $1.07 due to highlights of its new angiogenesis treatment for those suffering from heart disease.Cardiovascular disease is no doubt a big issue for not only those inflicted with it, but also for a highly scrutinized healthcare system, due to the cost of necessary treatments. This disease strikes over 36 percent of the population in the U.S., resulting in 2,400 deaths each day. With this in mind, people in the medical industry have been waiting a long time for a better approach to angiogenesis treatment, which is the growth of new blood vessels used to alleviate the decreased blood flow for patients with the disease.
CVBT, a biopharmaceutical company dealing with the production of protein drugs to treat cardiovascular disease, believes it has come up with new technology that will serve as an economic approach to treating the disease.
Fibroblast Growth Factor 1 (FGF-1), the new active pharmaceutical protein developed by CVBT, will stimulate new blood vessel growth. Currently, CVBT is working on ways to develop this protein into an injectable form and has passed the FDA-authorized Phase I study with FGF-1 administered to patients with severe Coronary Heart Disease. Studies have shown that FGF-1 can be applied to multiple tissues in the body that become injured due to decreased blood flow.
Shares of CardioVascular BioTherapeutics Inc. (OTCBB: CVBT) were flat today at $1.08 per share on volume of around 85 thousand shares. No recent news was available for CardioVascular.
The company’s stock has been in a steady decline over the past 52 weeks. The high around March/April last year was $8.02 per share and the share price has experienced a gradual decline to its current range.
The most recent company news comes from a press release back in the middle of February where CardioVascular announced that they had submitted a patent to the U.S. Patent and Trademark Office.
From the press release, SmallCap Sentinel analyst D.R. Clark said “It’s often among the first public steps a company can take in their pathway to market, and perhaps most importantly, it’s one of the few public steps about technology being developed.
Along these lines, CardioVascular BioTherapeutics, Inc. recently announced that the U.S. Patent and Trademark Office allowed the company’s patent application for delivery injection of the company’s protein drug candidate directly into the damaged heart muscle of patients suffering from coronary artery disease.”
On the day this news was released, CardioVascular’s shares traded in the range of $1.08 to $1.10 per share on light volume.
The most recent quarterly information for CardioVascular comes from the three month period ended September 30, 2006. The company has about $13 million cash which is essential for pharmaceutical companies developing new technologies or medications. CardioVascular is a development stage company with no revenues of any kind.
CardioVascular is a biopharmaceutical company developing formulations of its active pharmaceutical ingredient, Fibroblast Growth Factor-1, to treat a number of diseases characterized by inadequate blood flow to a tissue or organ.